Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

PMCB stock hub

PharmaCyte Biotech, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

PMCBis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

8.1M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

PMCB

In the news

Latest news · PMCB

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-8.2

P25 -105.6P50 -46.5P75 -3.1

ROIC-8.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All PMCB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

172

Groups with data

Currency

USD

Showing 172 of 172 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001157075
Company name	PharmaCyte Biotech, Inc.
Country	United States
Country code	US
Cusip	71715X203
Employees	2
Employees Change	-2%
Employees Change Percent	-50
Enterprise value	$-12.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US71715X2036
Last refreshed	2026-05-10
Market cap	$8.1M
Market cap category	Nano-Cap
Price	$0.76
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	PMCB
Website	https://pharmacyte.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-92.27%
P/B ratio	0.21x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-7.5M
Net Income Growth Quarters	1%
Net Income Growth Years	1%
Profit Per Employee	$-3.7M
Profitable Years	1
ROA	-6.75
Roa5y	-10.95
ROCE	-9.94
ROE	-8.24
Roe5y	-1.35
ROIC	-8.45

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-39.02%
Cagr15y	-23.67%
Cagr1y	-30.99%
Cagr20y	-27.38%
Cagr3y	-35.37%
Cagr5y	-49.38%
EPS Growth Quarters	1
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$55.9M
Cash	$20.5M
Current Assets	$20.7M
Current Liabilities	$1.7M
Equity	$39.4M
Liabilities	$16.5M
Long Term Assets	$35.2M
Long Term Liabilities	$14.8M
Net Cash	$20.5M
Net Cash By Market Cap	$253
Net Cash Growth	22.57%
Net Debt Equity	$-0.52
Tangible Book Value	$37M
Tangible Book Value Per Share	$3.44
WACC	6.76

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	12.33
Net Working Capital	$-1.5M
Quick ratio	12.24
Working Capital	$19M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	3.58%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.29%
1Y total return	-30.98%
200-day SMA	0.85
3Y total return	-73.01%
50-day SMA	0.72
50-day SMA vs 200-day SMA	50under200
5Y total return	-96.67%
All Time High	1,249.9
All Time High Change	-99.94%
All Time High Date	2003-10-08
All Time Low	0.63
All Time Low Change	19.97%
All Time Low Date	2025-11-20
ATR	0.06
Beta	0.46
Beta1y	0.76
Beta2y	0.81
Ch YTD	4.39
High	0.8
High52	1.51
High52 Date	2025-12-05
High52ch	-49.95%
Low	0.74
Low52	0.63
Low52 Date	2026-03-20
Low52ch	19.97%
Ma50ch	5.16%
Premarket Change Percent	-4.2
Premarket Price	$0.77
Premarket Volume	100
Price vs 200-day SMA	-11.37%
RSI	52.22
RSI Monthly	34.51
RSI Weekly	46.95
Sharpe ratio	-0x
Sortino ratio	0.07
Total Return	3.58%
Tr YTD	4.39
Tr15y	-98.26%
Tr1m	10.97%
Tr1w	0.07%
Tr3m	1.97%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-5.4M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	9,960,105%
Float Percent	92.78%
Shares Insiders	6.76%
Shares Institutions	9.62%
Shares Out	10,735,649
Shares Qo Q	36.3%
Shares Yo Y	-3.58%
Short Float	0.85%
Short Ratio	0.49
Short Shares	0.79

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	115,502.9x
Bv Per Share	3.59
Ch10y	-99.29
Ch15y	-98.26
Ch1m	10.97
Ch1w	0.07
Ch1y	-30.98
Ch20y	-99.83
Ch3m	1.97
Ch3y	-73.01
Ch5y	-96.67
Ch6m	-11.29
Change	-5.53%
Change From Open	-3.1
Close	0.8
Days Gap	-2.5
Dollar Volume	44,933.8
Earnings Date	2026-03-17
EBIT	$-5.4M
EPS	$-1.01
F Score	1
Financing CF	6,579,852
Fiscal Year End	April
Founded	1,996
Investing CF	2,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-17
Last Report Date	2026-01-31
Last Split Date	2021-07-12
Last Split Type	Reverse
Last10k Filing Date	2025-08-11
Ma150	0.81
Ma150ch	-7.09%
Ma20	0.75
Ma20ch	1.15%
Net CF	3,782,075
Next Earnings Date	2026-08-10
Open	0.78
Optionable	Yes
Position In Range	28.68
Post Close	0.76
Postmarket Change Percent	2.41
Postmarket Price	$0.77
Pre Close	0.8
Price Date	2026-05-08
Ptbv Ratio	0.22
Relative Volume	0.51x
Share Based Comp	1,137,920
Tr20y	-99.83%
Tr6m	-11.29%
Us State	Nevada
Volume	59,452

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does PMCB pay a dividend?

Capital-return profile for this ticker.

Performance

PMCB stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns PMCB?

Insider, institutional, and short-interest positioning.

Institutional ownership

+9.6%

Float: +92.8% of shares outstanding

Insider ownership

+6.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

PMCB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.2

Neutral momentum band

Price vs 200-day MA

-11.4%

50/200-day relationship not available

Beta (5Y)

0.46

Less volatile than the market

Sharpe ratio

-0.00

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About PMCB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current PMCB stock rating?

PharmaCyte Biotech, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full PMCB analysis?

The full report lives at /stocks/PMCB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for PMCB?

The latest report frames PMCB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the PMCB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.